Non-Small Cell Lung Cancer: Types, Pathogenesis, Diagnosis, and Novel Therapeutic Strategies

Year : 2026 | Volume : 16 | 02 | Page :
    By

    Nandini Rajendra Jadhav,

  • Dipti R. Rajput,

  • Devyani V. Dhangar,

  • Puja R. Chavhn,

  1. Assistant Professor, Department of Pharmaceutical Quality Assurances, SVS’s Dadashaheb Rawal Pharmacy College, Maharashtra, India
  2. Assistant Professor, Department of Pharmacognosy, SVS’s Dadashaheb Rawal Pharmacy College, Maharashtra, India
  3. Lecture, Department of Pharmacy, SVS’s Dadashaheb Rawal Pharmacy College, Maharashtra, India
  4. Student, Department of Pharmaceutical Quality Assurances, Arunamai College of Pharmacy, Maharashtra, India

Abstract

Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer, accounting for over 85% of all cases globally. It remains one of the primary causes of cancer-related death due to its rapid progression, few early symptoms, and late detection. The three main forms of non-small cell lung cancer (NSCLC) are adenocarcinoma, squamous cell carcinoma, and giant cell carcinoma; each has a unique histology, prognosis, and response to treatment. While genetic mutations, occupational carcinogens, environmental pollutants, and chronic lung disorders all have a major role in the development of the disease, tobacco smoking is the main etiological component. The accuracy of early detection and staging has increased thanks to developments in diagnostic methods such bronchoscopy, endobronchial ultrasonography, CT, PET imaging, and genomic profiling. Recent therapeutic developments, including targeted therapies against EGFR, ALK, ROS1, MET, RET, and KRAS mutations, along with immunotherapy and antibody-drug conjugates, have transformed NSCLC management and improved patient survival outcomes. Emerging approaches involving personalized medicine, artificial intelligence, and precision oncology are expected to further optimize diagnosis and treatment strategies. This review highlights the epidemiology, pathogenesis, classification, diagnosis, current therapeutic approaches, complications, and future innovations in NSCLC management.

Keywords: Non-small cell lung cancer (NSCLC), Adenocarcinoma, Squamous cell carcinoma, Large cell carcinoma, Lung Cancer, Targeted Therapy, EGFR Inhibitors, ALK inhibitors, Immunotherapy, Precision medicine, Molecular profiling, Diagnosis, Pathogenesis, Chemotherapy, Antibody-drug conjugates (ADCs)

How to cite this article:
Nandini Rajendra Jadhav, Dipti R. Rajput, Devyani V. Dhangar, Puja R. Chavhn. Non-Small Cell Lung Cancer: Types, Pathogenesis, Diagnosis, and Novel Therapeutic Strategies. Research and Reviews: A Journal of Pharmacology. 2026; 16(02):-.
How to cite this URL:
Nandini Rajendra Jadhav, Dipti R. Rajput, Devyani V. Dhangar, Puja R. Chavhn. Non-Small Cell Lung Cancer: Types, Pathogenesis, Diagnosis, and Novel Therapeutic Strategies. Research and Reviews: A Journal of Pharmacology. 2026; 16(02):-. Available from: https://journals.stmjournals.com/rrjop/article=2026/view=245720


References

1. Woo W, Park B, Ahadi A, Chung LI, Jung CM, Bharat A, Chae YK. The Role of Pulmonary Metastasectomy for Non-Primary Lung Cancer: Umbrella Review of Meta-Analyses. J Surg Oncol. 2025 May;131(6):1035-1043. doi: 10.1002/jso.28033. Epub 2024 Dec 15. PMID: 39674949; PMCID: PMC12131123.
2. Asmara OD, Hardavella G, Ramella S, et al. Stage III NSCLC treatment options: too many choices. Breathe 2024; 20: 240047 [DOI: 10.1183/20734735.0047-2024].
3. Ogita, S., & Wozniak, A. J. (2010). Refining the treatment of advanced nonsmall cell lung cancer. Lung Cancer: Targets and Therapy, 1, 9–22. https://doi.org/10.2147/lctt.s6075
4. Gerard A. et al.Journal of Thoracic Oncology, Screening Low-Risk Individuals for Lung Cancer: The Need May Be Present, but the Evidence of Benefit Is Not Silvestri, Volume 19, Issue 8, 1155 – 1163
5. Sunil Kumar Verma, Minakshi Pandey, Renu Khare, Devendra Singh, A review on non-small cell lung cancer, Vacunas, Volume 25, Issue 2,2024,Pages 239-253,ISSN 1576-9887, https://doi.org/10.1016/j.vacun.2023.12.003.
6. Toloza EM, Harpole L, McCrory DC. Non invasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003 Jan;123(1 Suppl):137S-146S.
7. Mujoomdar A, Austin JH, Malhotra R, Powell CA, Pearson GD, Shiau MC, Raftopoulos H. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology. 2007 Mar;242(3):882-8.
8. Clark SB, Alsubait S. Non–Small Cell Lung Cancer. [Updated 2023 Sep 4]. In: StatPearls. Treasure Island (FL):StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562307/
9. Electronic source Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. Sci Transl Med. 2013 Oct 30;5(209):209ra153.
10. Li S, Li W, Liu B, Krysan K, Dubinett SM. Noninvasive Lung Cancer Subtype Classification Using Tumor-Derived Signatures and cfDNA Methylome. Cancer Res Commun. 2024 Jul 1;4(7):1738-1747. doi: 10.1158/2767-9764.CRC-23-0564. PMID: 38856716; PMCID: PMC11249519.
11. Hilabi, B.S.; Alghamdi, S.A.; Almanaa, M. Impact of magnetic resonance imaging on healthcare in low- and middle-income countries. Cureus 2023, 15, e37698.
12. Funai K, Yokose T, Ishii G, Araki K, Yoshida J, Nishimura M, Nagai K, Nishiwaki Y, Ochiai A. Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung. Am J SurgPathol. 2003 Jul;27(7):978-84.
13. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I., WHO Panel. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015 Sep;10(9):1243-1260.
14. Mitchell RS, Kumar V, Abbas AK, Fausto N (2007). “morphology of adenocarcinoma”. Robbins Basic Pathology (8th ed.). Philadelphia: Saunders. ISBN 978-1-4160-2973-1.
15. Popper HH (2011). “Large cell carcinoma of the lung – a vanishing entity?”. Memo – Magazine of European Medical Oncology. 4: 4–9. doi:10.1007/s12254-011-0245-8. S2CID 71238993.
16. de Bruin EC, McGranahan N, Mitter R, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science. 2014 Oct 10. 346(6206):251-6.
17. Lee, J.Y.; Bhandare, R.R.; Boddu, S.H.S.; Shaik, A.B.; Saktivel, L.P.; Gupta, G.; Negi, P.; Barakat, M.; Singh, S.K.; Dua, K.; et al. Molecular mechanisms underlying the regulation of tumor suppressor genes in lung cancer. Biomed. Pharmacother. 2024, 173, 116275.
18. Biswas, B.; Talwar, D.; Meshram, P.; Julka, P.K.; Mehta, A.; Somashekhar, S.P.; Chilukuri, S.; Bansal, A. Navigating patient journey in early diagnosis of lung cancer in India. Lung India 2023, 40, 48–58.
19. Winston W Tan, MD, FACPNon-Small Cell Lung Cancer (NSCLC) Updated: Dec 02, 2025
20. Xiao, B.F.; Zhang, J.T.; Zhu, Y.G.; Cui, X.R.; Lu, Z.-M.; Yu, B.-T.; Wu, N. Chimeric antigen receptor T-cell therapy in lung cancer: Potential and challenges. Front. Immunol. 2021, 12, 782775.
21. Ito H, Matsuo K, Tanaka H, et al. Nonfilter and filter cigarette consumption and the incidence of lung cancer by histological type in Japan and the United States: analysis of 30-year data from population-based cancer registries. Int J Cancer. 2011 Apr 15. 128(8):1918-28.
22. Zhang J, Fujimoto J, Zhang J, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014 Oct 10. 346(6206):256-9.
23. Muminovic, M.; Carracedo Uribe, C.R.; Alvarez-Pinzon, A.; Shan, K.; Raez, L.E. Importance of ROS1 gene fusions in non-small cell lung cancer. Cancer Drug Resist. 2023, 6, 332.
24. Lee, J.Y.; Bhandare, R.R.; Boddu, S.H.S.; Shaik, A.B.; Saktivel, L.P.; Gupta, G.; Negi, P.; Barakat, M.; Singh, S.K.; Dua, K.; et al. Molecular mechanisms underlying the regulation of tumor suppressor genes in lung cancer. Biomed. Pharmacother. 2024, 173, 116275.
25. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008 May. 83(5):584-94.
26. Washington, DC.: National Academy Press,national Research Council, Committee on Health Risks of Exposure to Radon, Board on Radiation Effects Research, Commission on Life Sciences. Health effects of exposure to radon (BEIR VI).; 1999.
27. Gheisari, F.; Vali, R. Advancements in molecular imaging for the diagnosis and management of hepatocellular carcinoma. Med. Res. Arch. 2024, 12.
28. Electronic sources Cleveland Clinic(https://my.clevelandclinic.org/health/diseases/6203-non-small-cell-lung-cancer#overview)Last reviewed on 01/16/2025.
29. Brown, N.A.; Aisner, D.L.; Oxnard, G.R. Precision medicine in non-small cell lung cancer: Current standards in pathology and biomarker interpretation. Am. Soc. Clin. Oncol. Educ. Book 2018, 38, 708–715.
30. Electronic sources Clevel and Clinic(https://my.clevelandclinic.org/health/diseases/6203-non-small-cell-lung-cancer#overview)Last reviewed on 01/16/2025.
31. Electronic sources Yale medicine(https://www.yalemedicine.org/conditions/non-small-cell-lung-cancer)
32. Lung Cancer in Women: The Past, Present, and Future Florez, Narjust et al.Clinical Lung Cancer, Volume 25, Issue 1, 1 – 8
33. Lorigan P, Radford J, Howell A, Thatcher N. Lung cancer after treatment for Hodgkin’s lymphoma: a systematic review. Lancet Oncol. 2005 Oct;6(10):773-9.
34. Rebuzzi, S.E.; Zullo, L.; Rossi, G.; Grassi, M.; Murianni, V.; Tagliamento, M.; Prelaj, A.; Coco, S.; Longo, L.; Dal Bello, M.G.; et al. Novel Emerging molecular targets in non-small cell lung cancer. Int. J. Mol. Sci. 2021, 22, 2625.
35. Kaur, P.; Singh, S.K.; Mishra, M.K.; Singh, S.; Singh, R. Promising combinatorial therapeutic strategies against non-small cell lung cancer. Cancers 2024, 16, 2205.
36. Azar, F.E.; Azami-Aghdash, S.; Pournaghi-Azar, F.; Mazdaki, A.; Rezapour, A.; Ebrahimi, P.; Yousefzadeh, N. Cost-effectiveness of lung cancer screening and treatment methods: A systematic review of systematic reviews. BMC Health Serv. Res. 2017, 17, 413.
37. Dong, L.; Wang, W.; Li, A.; Kansal, R.; Chen, Y.; Chen, H.; Li, X. Clinical next generation sequencing for precision medicine in cancer. Curr. Genom. 2015, 16, 253–263.
38. Xia, Y.; Chen, Y.; Chen, J.; Gan, Y.; Su, C.; Zhang, H.; Long, E.; Yan, F.; Yang, Y. Measuring direct non-medical burden among patients with advanced non-small cell lung cancer in China: Is there a difference in health status? Front. Public Health 2023, 11, 1090623.
39. Yang, J.; Yang, W.; Zhang, J.; Huang, A.; Yin, S.; Zhang, H.; Luo, Z.; Li, X.; Chen, Y.; Ma, L.; et al. Non-small cell lung cancer and metabolism research from 2013 to 2023: A visual analysis and bibliometric study. Front. Oncol. 2024, 14, 1322090.
40. Wang, Y.; Guo, Z.; Li, Y.; Zhou, Q. Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non-small-cell lung carcinoma. Open Med. 2016, 11, 68–77.
41. Lu, S.; Kato, T.; Dong, X.; Ahn, M.-J.; Quang, L.-V.; Soparattanapaisarn, N.; Inoue, T.; Wang, C.-L.; Huang, M.; Yang, J.C.-H.; et al. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N. Engl. J. Med. 2024.
42. Maraqa, B.; Al-Ashhab, M.; Sughayer, M.A. Anaplastic lymphoma kinase rearrangements in patients with non-small cell lung cancer in Jordan. J. Int. Med. Res. 2022, 50, 3000605221104181.
43. Desai, A.; Lovly, C.M. Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: A narrative review. Transl. Lung Cancer Res. 2023, 12, 615–628.
44. Santarpia, M.; Massafra, M.; Gebbia, V.; D’Aquino, A.; Garipoli, C.; Altavilla, G.; Rosell, R. A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations. Transl. Lung Cancer Res. 2021, 10, 1536–1556.
45. Cascetta, P.; Sforza, V.; Manzo, A.; Carillio, G.; Palumbo, G.; Esposito, G.; Montanino, A.; Costanzo, R.; Sendomenico, C.; De Cecio, R.; et al. RET inhibitors in non-small-cell lung cancer. Cancers 2021, 13, 4415.
46. Qiao, M.; Jiang, T.; Liu, X.; Mao, S.; Zhou, F.; Li, X.; Zhao, C.; Chen, X.; Su, C.; Ren, S.; et al. Immune checkpoint inhibitors in EGFR-mutated NSCLC: Dusk or dawn? J. Thorac. Oncol. 2021, 16, 1267–1288.
47. Li, S.; de Camargo Correia, G.S.; Wang, J.; Manochakian, R.; Zhao, Y.; Lou, Y. Emerging targeted therapies in advanced non-small-cell lung cancer. Cancers 2023, 15, 2899.
48. La’ah, A.S.; Chiou, S.-H. Cutting-edge therapies for lung cancer. Cells 2024, 13, 436.
49. Houda, I.; Dickhoff, C.; Uyl-de Groot, C.A.; Damhuis, R.A.M.; Reguart, N.; Provencio, M.; Levy, A.; Dziadziuszko, R.; Pompili, C.; Di Maio, M.; et al. Challenges and controversies in resectable non-small cell lung cancer: A clinician’s perspective. Lancet Reg. Health Eur. 2024, 38, 100841.
50. Gristina, V.; La Mantia, M.; Iacono, F.; Galvano, A.; Russo, A.; Bazan, V. The emerging therapeutic landscape of ALK inhibitors in non-small cell lung cancer. Pharmaceuticals 2020, 13, 474.
51. Stein, J.N.; Rivera, M.P.; Weiner, A.; Duma, N.; Henderson, L.; Mody, G.; Charlot, M. Sociodemographic disparities in the management of advanced lung cancer: A narrative review. J. Thorac. Dis. 2021, 13, 3772–3800.
52. Parvaresh, H.; Roozitalab, G.; Golandam, F.; Behzadi, P.; Jabbarzadeh Kaboli, P. Unraveling the potential of ALK-targeted therapies in non-small cell lung cancer: Comprehensive insights and future directions. Biomedicines 2024, 12, 297.
53. Tsai, C.-M.; Lin, C.-H.; Chou, Y.-Y.; Jen, H.-Y.; Jain, S. Clinical applications of comprehensive genomic profiling in advanced non-small-cell lung cancer—A case series. Curr. Oncol. 2024, 31, 3161–3176.
54. Yang, X.; Tang, Z.; Li, J.; Jiang, J.; Liu, Y. Progress of non-small-cell lung cancer with ROS1 rearrangement. Front. Mol. Biosci. 2023, 10, 1238093.
55. Muminovic, M.; Carracedo Uribe, C.R.; Alvarez-Pinzon, A.; Shan, K.; Raez, L.E. Importance of ROS1 gene fusions in non-small cell lung cancer. Cancer Drug Resist. 2023, 6, 332.
56. Khunger, A.; Khunger, M.; Velcheti, V. Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: Clinical evidence and experience. Ther. Adv. Respir. Dis. 2018, 12, 1753466618767611.
57. Santarpia, M.; Massafra, M.; Gebbia, V.; D’Aquino, A.; Garipoli, C.; Altavilla, G.; Rosell, R. A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations. Transl. Lung Cancer Res. 2021, 10, 1536–1556.
58. Farhud, D.D.; Zokaei, S. Ethical issues of artificial intelligence in medicine and healthcare. Iran. J. Public Health 2021, 50, i–v.
59. Ando, K.; Manabe, R.; Kishino, Y.; Kusumoto, S.; Yamaoka, T.; Tanaka, A.; Ohmori, T.; Sagara, H. Comparative efficacy of ALK inhibitors for treatment-naïve ALK-positive advanced non-small cell lung cancer with central nervous system metastasis: A network meta-analysis. Int. J. Mol. Sci. 2023, 24, 2242.
60. Kanan, M.; Alharbi, H.; Alotaibi, N.; Almasuood, L.; Aljoaid, S.; Alharbi, T.; Albraik, L.; Alothman, W.; Aljohani, H.; Alzahrani, A.; et al. AI-driven models for diagnosing and predicting outcomes in lung cancer: A systematic review and meta-analysis. Cancers 2024, 16, 674.
61. Garg, P.; Mohanty, A.; Ramisetty, S.; Kulkarni, P.; Horne, D.; Pisick, E.; Salgia, R.; Singhal, S.S. Artificial intelligence and allied subsets in early detection and preclusion of gynecological cancers. Biochim. Biophys. Acta Rev. Cancer 2023, 1878, 189026.
62. Garg, P.; Singhal, S.; Kulkarni, P.; Horne, D.; Malhotra, J.; Salgia, R.; Singhal, S.S. Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions. J. Clin. Med. 2024, 13, 4189. https://doi.org/10.3390/jcm13144189
63. Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest. 2003 Jan;123(1 Suppl):21S-49S.
64. Lorigan P, Radford J, Howell A, Thatcher N. Lung cancer after treatment for Hodgkin’s lymphoma: a systematic review. Lancet Oncol. 2005 Oct;6(10):773-9.
65. Huang YJ, Huang TW, Lin FH, Chung CH, Tsao CH, Chien WC. Radiation Therapy for Invasive Breast Cancer Increases the Risk of Second Primary Lung Cancer: A Nationwide Population-Based Cohort Analysis. J Thorac Oncol. 2017 May;12(5):782-790.
66. Janssen-Heijnen ML, Coebergh JW, Klinkhamer PJ, Schipper RM, Splinter TA, Mooi WJ. Is there a common etiology for the rising incidence of and decreasing survival with adenocarcinoma of the lung? Epidemiology. 2001 Mar;12(2):256-8.
67. Jeon J, Holford TR, Levy DT, Feuer EJ, Cao P, Tam J, Clarke L, Clarke J, Kong CY, Meza R. Smoking and Lung Cancer Mortality in the United States From 2015 to 2065: A Comparative Modeling Approach. Ann Intern Med. 2018 Nov 20;169(10):684-693.]
68. Kish JK, Ro JY, Ayala AG, McMurtrey MJ. Primary mucinous adenocarcinoma of the lung with signet-ring cells: a histochemical comparison with signet-ring cell carcinomas of other sites. Hum Pathol. 1989 Nov;20(11):1097-102.
69. Sugimura H, Nichols FC, Yang P, Allen MS, Cassivi SD, Deschamps C, Williams BA, Pairolero PC. Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg. 2007 Feb;83(2):409-17; discussioin 417-8.
70. Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: clinical characteristics and evolving etiology. Medicine (Baltimore). 2006 Jan;85(1):37-42.
71. Siu AL., U.S. Preventive Services Task Force. Behavioral and Pharmacotherapy Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Women: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2015 Oct 20;163(8):622-34.
72. Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A, Saito R, Maruyama Y, Kawahara M, Ignatius Ou SH. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol. 2010 May;5(5):620-
73. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst. 1980 Jul;65(1):25-32.
74. D’Angelo SP, Janjigian YY, Ahye N, Riely GJ, Chaft JE, Sima CS, Shen R, Zheng J, Dycoco J, Kris MG, Zakowski MF, Ladanyi M, Rusch V, Azzoli CG. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol. 2012 Dec;7(12):1815-1822.
75. Paesmans M, Berghmans T, Dusart M, Garcia C, Hossein-Foucher C, Lafitte JJ, Mascaux C, Meert AP, Roelandts M, Scherpereel A, Terrones Munoz V, Sculier JP., European Lung Cancer Working Party, and on behalf of the IASLC Lung Cancer Staging Project. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol. 2010 May;5(5):612-9.
76. Sugimura H, Nichols FC, Yang P, Allen MS, Cassivi SD, Deschamps C, Williams BA, Pairolero PC. Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg. 2007 Feb;83(2):409-17; discussioin 417-8.
77. Mujoomdar A, Austin JH, Malhotra R, Powell CA, Pearson GD, Shiau MC, Raftopoulos H. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology. 2007 Mar;242(3):882-8.
78. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003 Jan;123(1 Suppl):137S-146S.
79. Kish JK, Ro JY, Ayala AG, McMurtrey MJ. Primary mucinous adenocarcinoma of the lung with signet-ring cells: a histochemical comparison with signet-ring cell carcinomas of other sites. Hum Pathol. 1989 Nov;20(11):1097-102.
80. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I., WHO Panel. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015 Sep;10(9):1243-1260.
81. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003 Jan;123(1 Suppl):137S-146S.
82. Mujoomdar A, Austin JH, Malhotra R, Powell CA, Pearson GD, Shiau MC, Raftopoulos H. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology. 2007 Mar;242(3):882-8.
83. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013
84. Bilger G, Girard N, Doubre H, et al: Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study. Cancer Immunol Immunother 71:1719-1731, 2022
85. Besse B, Felip E, Garcia Campelo R, et al: Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1. Ann Oncol 34:920-933, 2023
86. Beck A, Goetsch L, Dumontet C, et al: Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov 16:315-337, 2017
87. Hendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024). Non-small-cell lung cancer. Nature Reviews Disease Primers, 10(1), Article 71. https://doi.org/10.1038/s41572-024-00551-9
88. Thandra, K.C.; Barsouk, A.; Saginala, K.; Aluru, J.S.; Barsouk, A. Epidemiology of lung cancer. Contemp. Oncol. 2021, 25, 45–52.
89. Bray, F.; Laversanne, M.; Sung, H.; Ferlay, J.; Siegel, R.L.; Soerjomataram, I.; Jemal, A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024, 74, 229–263.
90. Cooper, W.A.; Lam, D.C.; O’Toole, S.A.; Minna, J.D. Molecular biology of lung cancer. J. Thorac. Dis. 2013, 5 (Suppl. S5), S479–S490.
91. Roh, M.S. Molecular pathology of lung cancer: Current status and future directions. Tuberc. Respir. Dis. 2014, 77, 49–54.
92. Boolell, V.; Alamgeer, M.; Watkins, D.N.; Ganju, V. The evolution of therapies in non-small cell lung cancer. Cancers 2015, 7, 1815–1846.
93. Smolarz, B.; Łukasiewicz, H.; Samulak, D.; Piekarska, E.; Kołaciński, R.; Romanowicz, H. Lung Cancer—Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature). Int. J. Mol. Sci. 2025, 26, 2049. https://doi.org/10.3390/ijms26052049
94. Janssen-Heijnen ML, Coebergh JW, Klinkhamer PJ, Schipper RM, Splinter TA, Mooi WJ. Is there a common etiology for the rising incidence of and decreasing survival with adenocarcinoma of the lung? Epidemiology. 2001 Mar;12(2):256-8.
95. Jeon J, Holford TR, Levy DT, Feuer EJ, Cao P, Tam J, Clarke L, Clarke J, Kong CY, Meza R. Smoking and Lung Cancer Mortality in the United States From 2015 to 2065: A Comparative Modeling Approach. Ann Intern Med. 2018 Nov 20;169(10):684-693.
96. Kish JK, Ro JY, Ayala AG, McMurtrey MJ. Primary mucinous adenocarcinoma of the lung with signet-ring cells: a histochemical comparison with signet-ring cell carcinomas of other sites. Hum Pathol. 1989 Nov;20(11):1097-102.
97. Kish JK, Ro JY, Ayala AG, McMurtrey MJ. Primary mucinous adenocarcinoma of the lung with signet-ring cells: a histochemical comparison with signet-ring cell carcinomas of other sites. Hum Pathol. 1989 Nov;20(11):1097-102.
98. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I., WHO Panel. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015 Sep;10(9):1243-1260.
99. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest. 2003 Jan;123(1 Suppl):137S-146S.
100. Mujoomdar A, Austin JH, Malhotra R, Powell CA, Pearson GD, Shiau MC, Raftopoulos H. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology. 2007 Mar;242(3):882-8.
101. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013 Jun;137(6):82

 

 

Ahead of Print Subscription Review Article
Volume 16
02
Received 20/05/2026
Accepted 01/06/2026
Published 02/06/2026
Publication Time 13 Days
25

Login


My IP

PlumX Metrics